Skip to main content
Premium Trial:

Request an Annual Quote

Battelle to Evaluate NGS for Forensics with $800K Award

NEW YORK (GenomeWeb) – Battelle today announced an $800,000 award from the National Institute of Justice to test next-generation sequencing tools for use in law enforcement.

Over a 19-month period, Battelle will conduct feasibility and validation tests on NGS instruments, laboratory materials, and software to assess their ability to "expand the probative information that may be obtained from forensic biological evidence," it said in a statement. The non-profit R&D organization also will evaluate biomarkers which could improve law enforcement's abilities to identify crime suspects and allow them to predict physical and ancestral characteristics to support investigations.

Working with other laboratories, Battelle will develop performance evaluation criteria and use genomic DNA samples provided by the National Institute of Standards and Technology to coordinate inter-laboratory studies, it said. The labs include the Armed Forces DNA Identification Laboratory; Bureau of Alcohol, Tobacco, Firearms, and Explosives; California Department of Justice; Harris County Institute of Forensic Sciences in Houston; NIST; Pennsylvania State University; and Philadelphia Police Department.

"Next-generation sequencing will significantly expand our technical capabilities to support forensic science, law enforcement, and ultimately the criminal justice system," said Rich Guerrieri, research leader for Battelle's applied genomics, and former chief of the FBI Laboratory's nuclear DNA casework and database units. "Evaluating a technology's reliability and assessing its limitations are critical steps in the development of quality practices and formation of a strategic roadmap for NGS implementation by forensic laboratories."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.